The transfer of genes encoding cytokines into tumor cells has emerged as a new strategy to increase in vivo host reactivity to a variety of tumors. Because gene transfer into tumor cells cannot be easily applied in the clinical setting, we have developed an experimental model of gene transfer into fibroblasts and examined the capacity of these engineered cells to elicit an antitumor immune response. Interleukin-12 (IL-12) is a heterodimeric cytokine with pleiotropic activities presenting strong antitumor and antimetastatic effects in murine models. A bicistronic retroviral vector was constructed that contained the cDNAs encoding both chains (p40 and p35) of murine IL-12 separated by an internal ribosomal entry site sequence. Syngeneic cutaneous fibroblasts obtained from newborn mice and transduced to secrete either IL-12 or IL-2 were injected subcutaneously with B16F0 or B16F1 melanoma cells. The time of tumor occurrence and overall survival of mice were significantly prolonged when B16F1 cells were coinjected with cytokine-producing fibroblasts compared with B16F1 alone or B16F1 together with unmanipulated fibroblasts. Systemic effects were seen in the mice injected with either IL-2-or IL-12-secreting fibroblasts, with the highest proliferation capability and interferon-␥ production observed in vitro from splenocytes from recipients of IL-2-secreting fibroblasts. Injection of IL-2-secreting fibroblasts or coinjection of IL-2-and IL-12-producing fibroblasts resulted in a significant increase of survival in the B16F0 model; in some cases, complete disease eradication was observed. These results suggest that cutaneous fibroblasts represent a target of choice for gene transfer and would be useful in the treatment of minimal residual disease in humans.
I mmunotherapy using cytokines and/or costimulatory molecules has emerged in recent years as an innovative strategy in the treatment of cancer. 1 The antitumor activity of a number of cytokines has been demonstrated in various animal tumor models. [2] [3] [4] [5] Interleukin-12 (IL-12) has attracted much enthusiasm in devising immunotherapeutic strategies. IL-12, a heterodimeric cytokine composed of two disulfide-linked subunits of ϳ40 and 35 kDa is naturally produced by activated antigen (Ag)-presenting cells. 6 -9 IL-12 functions as a growth factor of T and natural killer (NK) cells, promotes the development of cell-mediated immunity (T-helper type 1 cells), 9, 10 induces the secretion of interferon-␥ (IFN-␥) from resting and activated T and NK cells, and increases the cytotoxic activity of NK/lymphokine-activated killer cells and the specific cytotoxic T-lymphocyte (CTL) response. [11] [12] [13] [14] [15] In addition, IL-12 has been shown to present antiangiogenic properties. 16 IL-12 has been demonstrated to have important antitumor and antimetastatic effects against a number of murine tumors following administration by several routes. [17] [18] [19] [20] [21] [22] [23] [24] [25] Endogenous IL-12 appears necessary for tumor rejection, supporting its role in cancer immunotherapy. 26, 27 In vitro data suggest that a combination of IL-2 and IL-12 may result in additive or synergistic immunomodulatory effects, displaying a higher in vivo antitumor efficacy than that obtained with either cytokine alone. 20, 22 IL-2 can also enhance the expression of IL-12 receptors on T and NK cells. 28 The present study was designed to examine and compare the antitumor immunity induced by the administration of IL-2-or IL-12-transduced fibroblasts in two melanoma murine models, B16F0 and B16F1. The possible additive effect of the coexpression of IL-2 and IL-12 at the tumor site was also tested by the conjunctional use of IL-2-and IL-12-transduced fibroblasts. Furthermore, we explored the capacity of the host to mount a cell response to the cytokine produced. A bicistronic retroviral vector producing both genes p35 and p40 of IL-12 was constructed for this study.
MATERIALS AND METHODS

Construction of murine stem cell virus retroviral vector (MSCV)-IL-12 and -IL-2 retroviral vectors
The cDNA for the p40 and p35 subunits of murine IL-12 (mIL-12) was cloned into the MSCV. This vector contains a neo gene under the control of a phosphoglycerate kinase promoter. 29, 30 Polymerase chain reaction (PCR) amplification of the p40 subunit cDNA cloned in pBS vector (provided by M. K. Gately, Hoffmann-La Roche, Nutley, NJ) was performed in a 50-L volume containing 15 pmol of each primer, 80 M of deoxynucleoside triphosphate, 1 mM MgCl 2 , and 1.25 U Goldstar Taq polymerase (Eurogentec, Liège, Belgium) on an MJ Research thermocycler (Waltham, Mass). The primers used for p40 were 5Ј-GAACAAAAGTTAACGGGCTGCAG-GTCGATC-3Ј (sense) and 5Ј-TAGGGCCTCGAGCTAG-GATCGGACC-3Ј (antisense) and included restriction site sequences for HpaI and XhoI (underlined) in the sequence of the sense and antisense primers, respectively. PCR was performed for 30 cycles. Each cycle consisted of 94°C for 40 seconds, 65°C for 1 minute, and 72°C for 1.5 minutes. Similarly, p35 cDNA (provided by Hoffmann-La Roche) was amplified from cDNA cloned in a pBS vector using the following primers: 5Ј-AACAAAAGATCTGGCTGCAGGTCGATCG-3Ј (sense) and 5Ј-AGCTAAGATCTCTAATGAATTCTCA-3Ј (antisense) that contained BglII sites for cloning into MSCV (annealing temperature of 60°C). The expected lengths of resulting the p40 PCR and p35 products were 1053 base pairs and 649 base pairs, respectively. Amplified p40 and p35 products were ligated into the HpaI and XhoI and BglII sites of MSCV, respectively.
Between the two cDNAs, an intervening encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES) sequence obtained by PCR amplification of the pCITE plasmid (sense: 5Ј-ATAGGGAGACTCGAGTTCCGCCCC-3Ј and antisense 5Ј-GTTCCATGGCTCGAGCCATATTAT-3Ј) of the pCITE plasmid (Novagen, Abingdon, UK) was subcloned into the XhoI site at the 3Ј terminus of the p40 cDNA. The IRES sequence allowed for the coordinated expression of the two subunits as a bicistronic transcript in a cap-independent manner. 26, 27 Retrovirus vector constructs were transfected into the GPϩE86 murine ecotropic packaging cell line generously provided by A. Bank 31 (Columbia University, New York, NY) by standard calcium phosphate coprecipitation. The supernatant of the G418-resistant cells was used to infect the amphotropic PA317 packaging cell line provided by R. C. Mulligan (Howard Hughes Medical Institute, Harvard Medical School, Boston, Mass). 32 Under G418 selection (500 g/mL), several clones were isolated; the reverse transcriptase activity contained within the virus particles was measured to check for the presence of retrovirus in the conditioned media. The clones with the highest activity were titrated by supernatant infection of NIH3T3 cells. As the highest titer was only 6 ϫ 10 2 colony-forming units (CFU)/mL, the supernatant of this clone was used to infect the GPϩE86 cells. The absence of replication-competent virus in conditional medium was confirmed by a test measuring the reverse transcriptase activity contained in the viral particles by [ 3 H]thymidine incorporation of trichloroacetic acid-precipitable material. The MSCV-mIL-2 vector was constructed by inserting a 0. 6 cells/24 hours were calculated from a standard curve using defined doses of recombinant mIL-12 (rmIL-12), kindly provided by Maurice Gately (Hoffmann-La Roche), ranging from 15.6 pg/mL to 16 ng/mL. Measurements of the IL-12, IFN-␥, and IL-2 present in sera and culture supernatants were performed using enzyme-linked immunosorbent assay (ELISA) kits (Genzyme, Cambridge, Mass).
Cell lines
B16F0 and B16F1 melanomas and PA317 packaging cell lines were purchased from ATCC. GPϩE86 was kindly provided by Dr. A. Bank. 31 Tumor cells and GPϩE86 and PA317 packaging cell lines were maintained in culture in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, 100 g/mL streptomycin, and 100 U/mL penicillin (Life Technologies, Gaithersburg, Md). GPϩE86 cells were selected in HXM (hypoxanthine, xanthine, mycophenolic acid) medium as described previously. 30 The tumorigenic activity of B16F1 and B16F0 was assayed in mice that had been injected subcutaneously (s.c.) with 0.2 mL of serum-free phosphate-buffered saline (PBS) cell suspension at various concentrations to determine the minimal num- Animal experiments C57BL/6 mice were purchased from Iffa Credo (L'Arbresle, France) and used in experiments at 6 -10 weeks of age. Exponentially growing tumor cells were harvested by brief trypsination, washed, and used to inoculate groups of animals s.c. in the shaved area of the right flank. The number of mice for each group is specified in Results. The emergence of palpable tumors was examined every other day, and tumor size was determined by microcaliper measurement of perpendicular tumor diameters in millimeters. Used nontransduced or genetically modified fibroblasts were coadmixed with autologous tumor cells and injected in 0.2 mL of PBS at different B16F0 tumor to fibroblast (T:F) ratios (1:5 and 1:10).
Preparation and assay of syngeneic fibroblasts expressing IL-12 or IL-2
Syngeneic fibroblasts were obtained from the skin of newborn mice that had been mechanically and enzymatically digested with 0.25% collagenase (Sigma, St. Louis, Mo) and 4.8 U/mL dispase (grade II, Boehringer Mannheim, Mannheim, Germany) at 37°C for 1-2 hours under rotational agitation in the presence of RPMI 1640 supplemented with 20% fetal bovine serum (unpublished observations, N. Naffak, Institut Pasteur, Paris, France). After two washes in 1ϫ PBS, cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum. The following day, cells were infected by exposure to undiluted E86/MSCV-IL-12 or IL-2 supernatants for 2 hours a day in the presence of polybrene (8 g/mL; Life Technologies) for 5 consecutive days and subsequently selected for 3 days in complete medium with G418 at a concentration of 500 g/mL. IL-12 and IL-2 expression were measured in the supernatants by ELISA test.
Proliferation assay
Stimulation of 10 5 splenocytes was performed in 100 L of medium in round-bottom, 96-well microtiter plates (Falcon, Becton Dickinson) with concanavalin A (Con A) (2 g/mL), Con A plus IL-2 (2 ng/mL), Con A plus IL-12 (1.7 ng/mL), or medium alone. Addition of [ 3 H]thymidine and collection of samples were performed as described previously for IL-12 quantification.
Immunohistological analysis
Tumors were embedded into optimal cutting temperature compound (Miles, Elkert, Ind), snap-frozen in isopentane that had been precooled in liquid nitrogen, and stored at Ϫ80°C until sectioned. Briefly, tissue sections were prepared, fixed in cold acetone, and immunostained with rat anti-mouse monoclonal Ab (mAb) against CD8 (L3T4), CD4 (Ly-2), and CD11c (Mac-1␣M chain) cells (all purchased from PharMingen San Diego, Calif). Biotinylated mAbs were added at concentrations optimally titrated against mouse splenocytes and linked to streptavidin-peroxidase reagent. Sections were then incubated with peroxidase substrate (0.03% H 2 O 2 and 0.06% 3Ј-diaminobenzidine) and counter-stained with hematoxylin.
Statistics
The Student t test was performed to interpret the significance of difference between two experimental groups (presented as mean Ϯ SD). Kruskal-Wallis analysis was performed to compare differences in survival. Differences were considered to be statistically significant when the P value was Ͻ.05 (Dunn's test). 6 CFU/mL. An IL-12-producing cell line was obtained after transfection into GPϩE86 cells and serial infection of PA317 and GPϩE86 cells. Different clones were selected for their production of IL-12 using a human lymphoblast proliferation assay. The specificity of the IL-12 activity was confirmed using an Ab (C17.8) directed against p40 preventing the binding of IL-12 to its receptor (Fig 2) . One clone with a titer of 5 ϫ 10 3 CFU/mL-producing 260 ng IL-12/10 6 cells after 24 hours was isolated and termed E86/MSCV-IL-12. Supernatant of E86/MSCV-IL-12 was used to infect fibroblasts.
RESULTS
Construction of MSCV-IL
Generation of fibroblasts expressing IL-2 and IL-12
Virus-containing cell-free supernatants of E86/MSCV-IL-2 and E86/MSCV-IL-12 were used to infect autologous fibroblasts cells 2 hours a day for 5 consecutive days with renewal in infected cells of medium each day. Cells were subsequently selected for 3 days in G418. The presence of the provirus in infected cells was demonstrated by Southern blot analysis. IL-2 secretion was measured by ELISA performed on different supernatants. Production of the IL-12 by fibroblasts was measured in the supernatant using the proliferation assay after serial dilution and by ELISA. Both tests gave comparable values (Table 1) . (Table 2a ). The effect of IL-2 was directly dependent upon the number of fibroblasts injected, because no effects were observed for the 1:5 T:F ratio. Indeed, the tumor growth rate for the group of mice injected with the highest number of IL-2 fibroblasts (T:F ratio ϭ 1:10) was significantly reduced compared with that seen for mice treated with IL-2 at lower dose (T:F ratio ϭ 1:5) or with B16F0 alone or B16F0 and untransduced fibroblasts (P Ͻ .05; Student's t test). The combined injection of IL-2-and IL-12-producing cells at a 1:5:5 T:F:F ratio also delayed the appearance of tumors and reduced the tumor development rate (Table 2a) 
Growth of B16F0 tumor cells
IL-2-and IL-12-producing fibroblasts). The T:F ratio
(1:10) was the same as the ratio that gave optimal results in the previous experiments with B16F0. Effects of cytokine-engineered cells were evaluated by time of tumor appearance, growth rate, phenotype and cytokine production of splenocytes, and histological features at the tumor site.
Injections of B16F1 cells with cytokines producing fibroblasts delayed significantly the time of tumor occurrence in comparison with injections of B16F1 cells alone or mixed with unmanipulated fibroblasts (Table 2b) . By day 17, all control mice injected with tumor cells alone developed a tumor that grew progressively. Mice inoculated with untransduced fibroblasts showed tumor growth that was similar to that observed in mice injected with tumor cells alone. At 19 days postinjection, the mean tumor size for control mice was 69.5 Ϯ 56.8 mm 2 (n ϭ 14), whereas no tumor mass was detectable at this time in mice treated with fibroblasts genetically engineered to produce IL-12. The tumor growth rate for the groups of mice receiving IL-2-(T:F ratio ϭ 1:10), IL-12-(T:F ratio ϭ 1:10), or IL-2-and IL-12-(T:F ratio ϭ 1:5:5) transduced fibroblasts was significantly reduced compared with mice receiving B16F1 alone or B16F1 and untransduced fibroblasts (P Ͻ .05). No palpable tumor was observed in mice receiving IL-12-, IL-2-, or IL-2/IL-12-transduced fibroblasts before days 20, 13, and 15 respectively. For those groups, mean tumor sizes were 129 (Ϯ 70) mm 2 , 168 (Ϯ 130) mm 2 , and 122 (Ϯ 48) mm 2 by day 33; more than half of the mice injected with tumor cells alone were dead at that time (Student's t test; Fig 4) . IL-2-or IL-12-secreting fibroblasts at a 1:10 ratio or IL-2 and IL-12 at a T:F:F ratio of 1:5:5 prolonged median survival (in comparison with unmodified fibroblasts) by 9, 10.5, and 16 days, respectively (Fig 5) . These differences were statistically significant (Kruskal-Wallis (Dunn's test); P Ͻ .05). No statistically significant differences in time of tumor appearance were observed The results of the proliferation assays in the presence and absence of Con A are given in Figure 6 . No statistical difference was seen for the stimulation situations. The IL-12 secretion detected by ELISA in the sera was similar in the diverse groups (0.1 ng/mL). Only one mouse from the IL-12 group showed a low serum level of IFN-␥ (40 pg/mL). The detection of IFN-␥ by ELISA in splenocyte cell cultures in the presence or absence of Con A is shown in Figure 7 . Without Con A stimulation, IFN-␥ secretion was detected in mice injected with tumor cells and IL-2-producing fibroblasts. Following stimulation with Con A, a statistically significant increase of IFN-␥ was observed in mice receiving IL-2-producing fibroblasts (Student t test; P ϭ .039). No serum IL-2 was detected. A trace of IL-2 production was found in unstimulated splenocyte cell cultures (43 Ϯ 12 pg/mL for groups 1 and 3; 131 Ϯ 26 pg/mL for group 2). Three mice from each group were sacrificed at 30 days postinoculation. By immunohistochemical staining with mAb CD4, CD8, and CD11c, histological slides of tumors showed an abundant infiltration of macrophages in all cases, with few CD8 ϩ and without any CD4 ϩ ; no specific CTL response was observed in the spleens of injected mice in both tumor models (data not shown).
DISCUSSION
In the past few years, immunotherapy or gene therapy using cytokines has emerged as a new complementary approach to enhance host antitumor mechanisms of defense.
1 Several studies have demonstrated that administrations of exogenous cytokines in the area of growing tumors can induce a tumor-specific immune reaction involving various types of effector cells. Regional administration has been examined using peritumoral injections of cytokines, transduced tumor cells, and, more recently, modified fibroblasts. 3-5,27,34 -37 However, few comparative studies of cytokines alone or combined with costimulatory molecules have been conducted. Local de- livery of a low amount of cytokines directly to tumor cells also has the advantage of reducing the systemic toxicity associated with exogenous administration.
In this field, studies of various immunogenic and nonimmunogenic tumors in mice involving IL-12-engineered cells have shown that those cells were capable of augmenting T-cell-mediated tumor immunity, promoting the regression of well-established primary tumors, inhibiting the formation of metastases, and inducing a protective and long-lasting response when mice were rechallenged with unmodified parental tumor cells. 17,21,24 -25 A s.c. injection of allogenic or syngeneic fibroblast cell lines modified to produce IL-12 can prevent the development of tumors or treat effectively established tumors. 35, 37 In those models, rejection of a tumor requires several injections of IL-12-producing cells. IL-2 displays similar activities to those of IL-12, but its use is limited in the clinic because of its high toxicity. [38] [39] [40] IL-12 and IL-2 have demonstrated synergistic activities in vitro, namely through IFN-␥ production.
In the present study, we explored the antitumor efficiency of fibroblasts secreting cytokines at the tumor site. The difficulty in culturing, expanding, and infecting fresh human tumors limits their use as cellular vectors in the clinical setting. In addition, following in vitro culture of tumor cells, some tumor variants that may not represent the overall heterogeneity of the tumor might be expanded. Autologous cutaneous fibroblasts are readily accessible target cells that can be easily obtained from skin biopsies and outgrown in large-scale cultures. Their use in the clinic seems easily feasible and constitutes an attractive alternative method for gene therapy. Moreover, this route of administration of cytokines might be safer than systemic administration. [41] [42] [43] Because coexpression of the two subunits of mIL-12 is required to obtain an immunologically functional protein, 44 we have constructed a bicistronic MSCV-based retroviral vector 29 by inserting an IRES sequence from EMCV into a transcription unit to obtain the production of active IL-12. 45, 46 In mice, an excess of homodimeric p40 can inhibit heterodimeric IL-12. 47 In our construct, although p40 was subcloned upstream to p35 and could have been translated in excess, we did not observe this phenomenon. Using a PHA blast bioassay, the E86/ MSCV-IL-12 cell line and infected autologous fibroblasts produced moderate to high levels of bioactive mIL-12.
Using our retroviral construct and a MSCV-based IL-2 vector, we have examined the antitumor effects of cytokine paracrine production by transduced syngeneic murine skin fibroblasts on B16F0 and B16F1 melanoma tumor models. The antitumor efficacy of either IL-12 or IL-2 alone was compared with that obtained with IL-2 and IL-12 in combination.
Injection of fibroblasts had no effect on tumor growth. This indicates that fibroblasts by themselves do not induce an immune response that might have antitumor effects. However, IL-12 or IL-2-producing fibroblasts or the coinjection of IL-2 and IL-12-secreting fibroblasts delays development of the B16F1 tumor, even if no advantage was observed with coinjection in comparison with the use of either cytokine alone.
Production of cytokines and, in particular, IL-12 at the tumor site failed to induce a complete tumor rejection, even when relatively large amounts of IL-12 were produced by engineered fibroblasts (Յ260 ng/10 6 cells/24 hours), suggesting that the levels of those cytokines may be insufficient to maintain proper lymphocyte function for a long period. This may reflect the previous observation that IL-12 is more effective on established tumors rather than incipient tumors. 22 In addition, time schedules of IL-12 administration may have some importance in achieving antitumor activity. Martinotti et al have shown that the systemic effect of rIL-12 was linked to the time of treatment, because B16 tumors partially regressed in response to IL-12 but resumed growth after interruption of cytokine treatment. 48 As observed in the B16F1 model, there was no difference between the combination of IL-2 and IL-12 and IL-2 (T:F ratio ϭ 1:5:5) alone in mice bearing B16F0 melanoma. B16F0 tumor establishment was delayed in those mice receiving IL-2-transduced fibroblasts (T:F ratio ϭ 1:10) or a mixture of IL-2-and IL-12-transduced fibroblasts compared with tumor cells alone with or without untransduced fibroblasts. In the groups receiving transduced fibroblasts, a few mice did not develop any tumors.
An additive effect between IL-2 and IL-12 (ratio T:F ϭ 1:5:5) was observed with numbers of fibroblasts that did not induce any effect for either cytokine alone (T:F ϭ 1:5). IL-12 at a low dose may potentiate the IL-2 activation of CD8 ϩ T cells by acting in particular on the T helper type 1 subset of CD4 ϩ T cells using their helper stimulating function of cytotoxic cells responding to B16F0 or, alternatively, may amplify the activation of NK function or reduce the suppressive effect of IL-2.
As for IL-12 and IL-2 used alone, depletion studies using Abs directed against CD4, CD8, NK, macrophage T cells, and IFN-␥ depletion are needed to reveal the potential role of these subsets in the observed effects. Indeed, the determination of how long fibroblasts are able to produce cytokines must be of primordial importance in those experiments. Variations in the expression of costimulatory molecules and tumor Ags may certainly play a role and may partially explain why IL-12 has less of an effect on B16F0 tumorigenesis than that seen for B16F1. Both tumors have little or no expression of major histocompatibility complex class I molecules and low levels of B7. This may explain why we did not observe any primary immune response specific for the tumor and why experiments that examined the immunogenicity of antitumor formulation did not give us a clear explanation of the response induced. Indeed, we were unable to demonstrate a splenocyte CTL activity specific for B16F1 cells or T-cell infiltration at the tumor site in our model. This absence of CTL activity may reflect the poor immunogenicity of B16F1 cells lacking costimulatory and adhesion molecules. Cooperation between B7-1 and IL-12 has been shown to be more effective than immunization with either immunomodulator alone. 19, 43, 49 Even if no CTL activity could be obtained, a systemic response was induced, as splenocytes from mice injected with IL-2 and IL-12 fibroblasts showed a higher proliferative response and higher IFN-␥ production compared with that observed in B16F1-bearing mice.
The mechanism of IL-12-induced antitumor immunity is possibly dependent upon the presence of both T cells and IFN-␥. 50 The latter seems to be responsible for an initial antitumor response by increasing tumor Ag presentation through major histocompatibility complex class I induction of expression and consequently increasing presentation to CD8 ϩ T cells. 51 In conclusion, the present study gives more evidence of the antitumor efficacy of a combination of IL-2 and IL-12. Multiple injections of a combination of IL-2-and IL-12-producing fibroblasts might be considered to obtain tumor eradication. Immunotherapy such as that described here could be useful in the context of minimal residual malignant disease left by cytotoxic chemotherapy. The use of IL-12-or IL-2-producing fibroblasts in conjunction or not with irradiated tumor cells as a source of tumor Ag is an attractive approach, because this setting should be applicable in clinical situations in which the tumor mass is reduced to its minimal volume.
